LACRISERT (hydroxypropyl cellulose) by Bausch + Lomb is clinical pharmacology pharmacodynamics lacrisert acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. Approved for moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. First approved in 1981.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
LACRISERT is a hydroxypropyl cellulose ophthalmic insert approved in 1981 for moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. It works by stabilizing and thickening the precorneal tear film, prolonging tear film breakup time, and lubricating/protecting the eye. The insert dissolves gradually over 14-24 hours, providing sustained relief superior to artificial tears.
This product is approaching loss of exclusivity with minimal current spending and very low claim volume, indicating a small, mature franchise with limited team growth opportunity.
CLINICAL PHARMACOLOGY Pharmacodynamics LACRISERT acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. LACRISERT also acts to lubricate and protect the eye. LACRISERT usually reduces the signs and…
Worked on LACRISERT at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on LACRISERT offers stability in a niche ophthalmic franchise but limited growth upside; roles are best suited for professionals focused on maximizing market share in a mature segment, optimizing payer relationships, and managing a small brand team. Career advancement will require strong operational and managed care expertise rather than launch or expansion leadership.